A five-day course of molnupiravir, the new medicine being hailed as a "huge advance" in the treatment of Covid-19, costs $17.74 to produce, according to a report issued last week by drug pricing experts at the Harvard School of Public Health and King's College Hospital in London. Merck is charging the U.S. government $712 for the same amount of medicine, or 40 times the price. Like the vast majority of medicines on the market, molnupiravir " which was originally investigated as a possible treatment for Venezuelan equine encephalitis " was developed using government funds. The Defense Threat Reduction Agency, a division of the Department of Defense, provided more than $10 million of funding in 2013 and 2015 to Emory University, as research done by the nonprofit Knowledge Ecology International has revealed. The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, also provided Emory with more than $19 million in additional grants. Yet only Merck and Ridgeback will reap the profits from the new antiviral, which ... could bring in as much as $7 billion by the end of this year. After the announcement of the encouraging clinical trial results on Friday, Merck's stock price climbed. Good government advocates are pointing out that because federal agencies spent at least $29 million on the drug's development, the government has the obligation to ensure that the medicine is affordable.